Supporting patient care
At Mayo Clinic, we offer a comprehensive approach to neuro-oncology testing that focuses on the best outcomes for the patient. Our advanced genetic testing combines molecular and cytogenetic analysis to complement standard morphological and histological assessment. This maximizes the amount of available information, and provides a clear picture of the diagnosis, prognosis, and treatment options.
A complete assessment
A clear diagnosis
By performing immunohistochemical, molecular, and cytogenetic
analysis on all patients, our testing approach provides a more
complete assessment of the patient’s diagnosis, prognosis, and
Broad molecular and cytogenetic information is needed for all
patients in order to select the most appropriate treatment options,
whether standard, off-label, or clinical trial.
Understanding specific molecular markers is necessary to making
a diagnosis that meets classification guidelines and can guide
treatment decisions and therapeutic timelines.
Comprehensive genetic profiling for
Mayo Clinic is recognized worldwide for providing care for complex diseases including brain tumors. With rapid technological advancements and medical discoveries, the standard approach to genetic testing is evolving. In a clinical study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in significant, and sometimes unexpected, patient impact.
Clinical Relevance: Findings in Glioma Patients
In a Mayo Clinic study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in
a significant positive impact on patients. Of 400 patients seen, 75% received diagnostic, prognostic,
and/or predictive information.
of patients received one or more clinically actionable findings as a result of comprehensive molecular and cytogenetic testing.
of cases reported diagnostic findings
of cases reported prognostic findings
of cases reported predictive findings
Need content here if we want a feature block.
A Test in Focus
Featured content here.
Webinar - Molecular grouping of gliomas: clinical implications and utility
The "Specialty Testing" webinar, presented by Robert Jenkins, M.D., will briefly cover the current knowledge concerning the molecular genetic classification of adult gliomas.